[8] [9] [10] [11] Following initial development at the University of Arizona as a sunless tanning agent, the Australian company Clinuvel conducted further clinical trials in that and other indications, and brought the drug to market in the European Union, the United States, and Australia
Table 5 Comparison of insulin delivery technologies (225)
In a landmark 12-week-long health experiment, AOD-9604 produced intriguing results: participants who received AOD-9604 (1mg/day) experienced a greater weight loss compared to the placebo group, shedding an average of 2.6 kg compared to the placebo group's 0.8 kg
However, the result faded after 3 months, which made the researchers debate whether the impact could be from the initial frequent provider visits, motivated lifestyle choices, or the excessive nausea and malaise experienced on initiation of GLP-1 receptor agonists, which could have reduced the alcohol intake during the first few months